Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.55 |
| ▸ | CA1 | P00915 | 4/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.54 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.54 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.54 |
| ▸ | HPGDS | O60760 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | CASR | P41180 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1767668 | 1.00 | CA2 (0.55) | CA2CA1CA12CA9ERAP2 | |
| SCHEMBL6815759 | 1.00 | CA2 (0.55) | CA2CA1CA12CA9ERAP2 | |
| Hydrochloric Acid SCHEMBL2327717 | 0.99 | CA2 (0.54) | CA2CA1CA12CA9ERAP2 | |
| SCHEMBL9716692 | 0.89 | CA2 (0.55) | CA2CA1CA12CA9ERAP2 | |
| SCHEMBL24518200 | 0.89 | CA2 (0.55) | CA2CA1CA12CA9ERAP2 | |
| SCHEMBL9716715 | 0.87 | ERAP2 (0.55) | CA2CA1CA12CA9ERAP2 | |
| SCHEMBL9716710 | 0.87 | ERAP2 (0.55) | CA2CA1CA12CA9ERAP2 | |
| SCHEMBL7034241 | 0.87 | LNPEP (0.60) | CA2CA1CA12CA9ERAP2 | |
| SCHEMBL7034236 | 0.87 | LNPEP (0.60) | CA2CA1CA12CA9ERAP2 | |
| SCHEMBL607885 | 0.87 | ITGB3 (0.60) | CA2CA1CA12CA9ERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106139158-B | Growth hormone with prolonged in vivo efficacy | 诺沃—诺迪斯克保健股份有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20200102568-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2020-04-02 | — | — | US | disclosed |
| EP-2525834-B1 | GROWTH HORMONES WITH PROLONGED IN-VIVO EFFICACY | NOVO NORDISK HEALTHCARE AG (CH) | 2019-07-17 | — | — | EP | disclosed |
| US-20170239362-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2017-08-24 | — | — | US | disclosed |
| US-9695226-B2 | Growth hormones with prolonged in-vivo efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2017-07-04 | — | — | US | disclosed |
| US-8865868-B2 | Conjugated proteins with prolonged in vivo efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-8779109-B2 | Growth hormones with prolonged in-vivo efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2014-07-15 | — | — | US | disclosed |
| US-20140107324-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2014-04-17 | — | — | US | disclosed |
| US-20120309944-A1 | Growth Hormones With Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2012-12-06 | — | — | US | disclosed |
| EP-2525834-A1 | GROWTH HORMONES WITH PROLONGED IN-VIVO EFFICACY | Novo Nordisk Health Care AG (CH) | 2012-11-28 | — | — | EP | disclosed |
| US-20110223151-A1 | CONJUGATED PROTEINS WITH PROLONGED IN VIVO EFFICACY | NOVO NORDISK HEALTH CARE AG (CH) | 2011-09-15 | — | — | US | disclosed |
| WO-2011089255-A1 | GROWTH HORMONES WITH PROLONGED IN-VIVO EFFICACY | NOVO NORDISK HEALTH CARE AG (CH) | 2011-07-28 | — | — | WO | disclosed |
| EP-2323694-A1 | CONJUGATED PROTEINS WITH PROLONGED IN VIVO EFFICACY | Novo Nordisk Health Care AG (CH) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010015668-A1 | CONJUGATED PROTEINS WITH PROLONGED IN VIVO EFFICACY | NOVO NORDISK A/S (DK) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102568-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | SHBG, GHRHR, GHITM | CA2 4740/4885CA1 3769/4885CA12 3128/4885 |
| US-20120309944-A1 | Growth Hormones With Prolonged In-Vivo Efficacy | GHRHR, SHBG, GHSR | CA2 4691/4885CA1 3814/4885CA12 2840/4885 |
| US-20170239362-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | SHBG, GHRHR, GHITM | CA2 4740/4885CA1 3769/4885CA12 3128/4885 |
| US-20140107324-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | SHBG, GHRHR, GHITM | CA2 4740/4885CA1 3769/4885CA12 3128/4885 |
| US-20110223151-A1 | CONJUGATED PROTEINS WITH PROLONGED IN VIVO EFFICACY | F13B, F13A1, F2 | CA2 4295/4885CA1 3642/4885CA12 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.